The predictive value of steatosis in hepatitis C virus infection

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 3, 2013, Pages 205-213

  Adinolfi, Luigi E ^a   Restivo, Luciano ^a   Marrone, Aldo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

atherosclerosis; HCV; hepatocellular carcinoma; insulin resistance; liver fibrosis; steatosis

Indexed keywords

ANTILIPEMIC AGENT; ANTIVIRUS AGENT; INTERFERON; METFORMIN; THIAZOLIDINE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; CLINICAL FEATURE; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER FIBROSIS; METABOLIC DISORDER; METABOLIC STEATOSIS; METABOLIC SYNDROME X; NONHUMAN; PREDICTION; PREDICTIVE VALUE; STEATOSIS; VIRAL STEATOSIS; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS; FATTY LIVER; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLIC SYNDROME X; MODELS, STATISTICAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 84874631093     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.13.7     Document Type: Article

References (67)

1. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126(2), 586-597 (2004).
2. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 78(Pt 7), 1527-1531 (1997).
3. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33(6), 1358-1364 (2001).
4. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36(5), 1266-1272 (2002).
5. Hourioux C, Patient R, Morin A et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 56(9), 1302-1308 (2007).
6. Perlemuter G, Sabile A, Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 16(2), 185-194 (2002).
7. Mirandola S, Realdon S, Iqbal J et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130(6), 1661-1669 (2006).
8. Zampino R, Ingrosso D, Durante-Mangoni E et al. Microsomal triglyceride transfer protein (MTP)-493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J. Viral Hepat. 15(10), 740-746 (2008).
9. Mirandola S, Osterreicher CH, Marcolongo M et al. Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C. Liver Int. 29(4), 557-565 (2009).
10. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J. Viral Hepat. 13(2), 73-80 (2006).
11. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 33(1), 106-115 (2000).
12. Adinolfi LE. Hepatitis C and fatty liver. In: Hot Topics in Viral Hepatitis, Hepatitis C and Metabolism. Negro F (Ed.). FB Communication, Modena, Italy, 21-29 (2008).
13. Durante-Mangoni E, Zampino R, Marrone A et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-α in chronic hepatitis C patients. Aliment. Pharmacol. Ther. 24(9), 1349-1357 (2006).
14. Adinolfi LE, Ingrosso D, Cesaro G et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 41(5), 995-1003 (2005).
15. Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53(3), 791-799 (2011).
16. Zampino R, Coppola N, Cirillo G et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J. Viral Hep. doi:10.1111/jvh.12053 (2013) (Epub ahead of print).
17. Adinolfi LE, Utili R, Attanasio V et al. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital. J. Gastroenterol. 28(1), 1-9 (1996).
18. Khattab MA, Eslam M, Alavian SM. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat. Mon. 10(4), 258-269 (2010).
19. Durante-Mangoni E, Iardino P, Resse M et al. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J. Clin. Gastroenterol. 38(10), 901-905 (2004).
20. André P, Komurian-Pradel F, Deforges S et al. Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76(14), 6919-6928 (2002).
21. Serfaty L, Poujol-Robert A, Carbonell N, Chazouillères O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am. J. Gastroenterol. 97(7), 1807-1812 (2002).
22. Choi J. Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. Free Radic. Biol. Med. 52(7), 1135-1150 (2012).
23. Sevastianos VA, Hadziyannis SJ. Nonalcoholic fatty liver disease: from clinical recognition to treatment. Expert Rev. Gastroenterol. Hepatol. 2(1), 59-79 (2008).
24. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29(4), 1215-1219 (1999).
25. Fartoux L, Chazouillères O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 41(1), 82-87 (2005).
26. Rubbia-Brandt L, Fabris P, Paganin S et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 53, 406-412 (2004).
27. Castéra L, Hézode C, Roudot-Thoraval F et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 53(3), 420-424 (2004).
28. Castéra L, Hézode C, Roudot-Thoraval F et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52(2), 288-292 (2003).
29. Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J. Viral Hepat. 16(7), 492-499 (2009).
30. Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53(3), 413-419 (2004).
31. Restivo L, Guerrera B, Ciervo A et al. Factors and mechanisms involved in the progression of hepatic fibrosis in chronic HCV infection: which role for steatosis and insulin resistance? Intern. Emerg. Med. 7(Suppl. 4), S463-S464 (2012).
32. Leandro G, Mangia A, Hui J et al.; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130(6), 1636-1642 (2006).
33. Vidali M, Tripodi MF, Ivaldi A et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J. Hepatol. 48(3), 399-406 (2008).
34. Del Campo JA, Romero-Gómez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J. Gastroenterol. 15(40), 5014-5019 (2009).
35. Seidel N, Volkmann X, Länger F et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 42, 113-120 (2005).
36. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4(9), 1065-1067 (1998).
37. Ohata K, Hamasaki K, Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97(12), 3036-3043 (2003).
38. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 109(12), 2490-2496 (2007).
39. Nkontchou G, Ziol M, Aout M et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J. Viral Hepat. 18(10), e516-e522 (2011).
40. Tazawa J, Maeda M, Nakagawa M et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig. Dis. Sci. 47(4), 710-715 (2002).
41. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br. J. Cancer 97(7), 1005-1008 (2007).
42. Chen CL, Yang HI, Yang WS et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135(1), 111-121 (2008).
43. Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J. Gastroenterol. Hepatol. 20(9), 1395-1400 (2005).
44. Jahan S, Ashfaq UA, Qasim M, Khaliq S, Saleem MJ, Afzal N. Hepatitis C virus to hepatocellular carcinoma. Infect. Agents Cancer 7(1), 2 (2012).
45. Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin. Pharmacother. 12(14), 2215-2234 (2011).
46. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125(6), 1695-1704 (2003).
47. Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134(2), 416-423 (2008).
48. Tsochatzis E, Manolakopoulos S, Papatheodoridis GV et al. Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. Aliment. Pharmacol. Ther. 30(9), 947-954 (2009).
49. Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev. Anti. Infect. Ther. 7(3), 293-308 (2009).
50. Petta S, Cammà C, Di Marco V et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am. J. Gastroenterol. 103(5), 1136-1144 (2008).
51. Kwon SY, Kim SS, Kwon OS et al. Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet. Med. 22(11), 1530-1535 (2005).
52. Lonardo A, Ballestri S, Adinolfi LE et al. Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can. J. Gastroenterol. 23(4), 273-278 (2009).
53. Adinolfi LE, Restivo L, Zampino R et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 221(2), 496-502 (2012).
54. Ishizaka N, Ishizaka Y, Takahashi E et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359(9301), 133-135 (2002).
55. Lonardo A, Ballestri S, Restivo L et al. Hepatitis C and cardiovascular risk: facts and controversies. In: Hot Topics in Viral Hepatitis, Hepatitis C and Metabolism (3rd Edition). Negro F (Ed.). FB Communication, Modena, Italy, 27-33 (2012).
56. Boddi M, Abbate R, Chellini B et al. Hepatitis C virus RNA localization in human carotid plaques. J. Clin. Virol. 47, 72-75 (2010).
57. Petta S, Torres D, Fazio G et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 55(5), 1317-1323 (2012).
58. Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS ONE 7(2), e31527 (2012).
59. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon α-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38(1), 75-85 (2003).
60. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 40(3), 484-490 (2004).
61. Westin J, Lagging M, Dhillon AP et al.; DITTO-HCV Study Group. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J. Viral Hepat. 14(1), 29-35 (2007).
62. Tarantino G, Conca P, Ariello M, Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 55(4), 585 (2006).
63. Shah SR, Patel K, Marcellin P et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin. Gastroenterol. Hepatol. 9(8), 688-693 (2011).
64. Restivo L, Zampino R, Guerrera B, Ruggiero L, Adinolfi LE. Steatosis is the predictor of relapse in HCV genotype 3-but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR. J. Viral Hepat. 19(5), 346-352 (2012).
65. Shiffman ML, Suter F, Bacon BR et al.; ACCELERATE Investigators. Peginterferon α-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357(2), 124-134 (2007).
66. Gundez F, Adoulnasr FM, Chandra PK et al. Free fatty acids induce ER stress and block antiviral activity of interferon α against hepatitis C virus in cell culture. Virol. J. 9, 143 (2012).
67. Walch MJ, Johnson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55, 529-535 (2006).